Literature DB >> 3746635

An enzyme-distributed system for lidocaine metabolism in the perfused rat liver preparation.

K S Pang, J A Terrell, S D Nelson, K F Feuer, M J Clements, L Endrenyi.   

Abstract

The influence of enzymic distribution on lidocaine metabolism was investigated in the once-through perfused rat liver preparation. Low input concentrations of 14C-lidocaine (1-2 microM) and preformed monoethylglycine xylidide (MEGX; 2.3-2.8 microM) were delivered by normal and retrograde flow directions to the liver preparations at 10 ml/min per liver. Upon reversal of normal to retrograde delivery of lidocaine, the rates at which lidocaine, MEGX, and glycine xylidide (GX) left the liver almost doubled, whereas the rates of appearance of (total) hydroxylated lidocaine and MEGX in bile and perfusate increased to lesser extents. Upon reversal of normal to retrograde delivery of preformed MEGX, the rates of appearance of MEGX and GX were virtually unchanged. Computer simulations on lidocaine and preformed MEGX metabolism were performed on both evenly distributed ("parallel tube" model) and enzyme-distributed systems. An even or parallel distribution of N-deethylation and hydroxylation activities for lidocaine metabolism failed to predict the observed increased hepatic availability of lidocaine. Rather, the distribution of a low-affinity, high-capacity N-deethylation system anterior to a high-affinity, low-capacity hydroxylation system for lidocaine metabolism adequately predicted the increased hepatic availability of lidocaine. Further extension of these consistent enzyme-distributed models on the metabolism of lidocaine metabolites suggests that the N-deethylation and hydroxylation activities for the metabolism of lidocaine, MEGX, 3-hydroxyidocaine, and 3-hydroxy MEGX are not identically distributed. When these enzyme-distributed models were appraised with reference to the "parallel tube" and "well-stirred" models of hepatic drug clearance, predictions from these enzyme-distributed models proved to be superior to the "parallel tube" and "well-stirred" models for the present data on lidocaine metabolites with normal and retrograde perfusions. Previously published data on lidocaine and MEGX metabolism after inputting 4 micrograms/ml (17 microM) lidocaine at flow rates of 10, 12, 14, and 16 ml/min were reexamined with respect to the adequacy of these enzyme-distributed models. They were found to be superior to the evenly-distributed or "parallel tube" model in predicting hepatic availability of lidocaine and the rate of appearance of MEGX. However, the enzyme-distributed systems were not as consistent as the "well-stirred" model in predicting lidocaine hepatic availability in these flow experiments.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3746635     DOI: 10.1007/bf01065257

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  41 in total

1.  Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  H J Pfeifer; D J Greenblatt; J Koch-Weser
Journal:  Am Heart J       Date:  1976-08       Impact factor: 4.749

Review 2.  Reevaluating the use of lidocaine.

Authors:  M A Nevins
Journal:  Geriatrics       Date:  1973-08

3.  Anti-arrhythmic effects of lidocaine metabolites.

Authors:  R G Burney; C A DiFazio; M J Peach; K A Petrie; M J Silvester
Journal:  Am Heart J       Date:  1974-12       Impact factor: 4.749

4.  The convulsant potency of lidocaine and its N-dealkylated metabolites.

Authors:  J Blumer; J M Strong; A J Atkinson
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

5.  Aromatic hydroxylation of lidocaine and mepivacaine in rats and humans.

Authors:  J Thomas; P Meffin
Journal:  J Med Chem       Date:  1972-10       Impact factor: 7.446

6.  Precursor-metabolite interaction in the metabolism of lidocaine.

Authors:  T Suzuki; S Fujita; R Kawai
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

7.  Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading.

Authors:  W W Stargel; D G Shand; P A Routledge; A Barchowsky; G S Wagner
Journal:  Am Heart J       Date:  1981-11       Impact factor: 4.749

8.  Bupivacaine and lignocaine induced seizures in rhesus monkeys.

Authors:  E S Munson; R W Martucci; I H Wagman
Journal:  Br J Anaesth       Date:  1972-10       Impact factor: 9.166

9.  Evidence for two catalytically different binding sites of liver microsomal cytochrome P-450: importance for species and sex differences in oxidation pattern of lidocaine.

Authors:  C von Bahr; I Hedlund; B Karlén; D Bäckström; H Grasdalen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-07

10.  Time-dependent kinetics of lignocaine in the isolated perfused rat liver.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacokinet Biopharm       Date:  1983-04
View more
  8 in total

1.  Availability predictions by hepatic elimination models for Michaelis-Menten kinetics.

Authors:  M S Roberts; J D Donaldson; D Jackett
Journal:  J Pharmacokinet Biopharm       Date:  1989-12

2.  A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination.

Authors:  M V St-Pierre; P I Lee; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-04

3.  Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.

Authors:  L P Rivory; M S Roberts; S M Pond
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

4.  Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 2. Effect of pharmacological agents, retrograde perfusions, and enzyme inhibition on evans blue, sucrose, water, and taurocholate.

Authors:  M S Roberts; S Fraser; A Wagner; L McLeod
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

5.  Metabolite mean transit times in the liver as predicted by various models of hepatic elimination.

Authors:  G D Mellick; Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

6.  Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver.

Authors:  X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1989-12

7.  Quantification of three lidocaine metabolites and their conjugates.

Authors:  Y K Tam; J Ke; R T Coutts; D G Wyse; M R Gray
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

8.  Competing pathways in drug metabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver.

Authors:  M E Morris; V Yuen; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.